Novo Nordisk’s exclusive negotiations to acquire a controlling stake in BIOCORP, a French medical device company, marks a significant step in the company’s strategy to enhance its capabilities in developing innovative injection devices and connected delivery solutions. The proposed acquisition includes the purchase of BIO JAG’s entire stake in BIOCORP, along with commitments from certain minority shareholders, representing a total equity value of approximately 154 million Euros.
BIOCORP’s expertise in the design and manufacturing of delivery systems, including their flagship product Mallya, a Bluetooth-enabled smart add-on device for pen injectors, aligns well with Novo Nordisk‘s focus on advancing connected healthcare solutions. The companies have already collaborated on the development of the Mallya add-on device for Novo Nordisk’s FlexTouch pen, used by people with diabetes.
By integrating BIOCORP’s capabilities and talent, Novo Nordisk aims to accelerate its efforts in delivering cutting-edge devices and delivery solutions to improve care for individuals living with chronic diseases worldwide. The company seeks to preserve the agility and entrepreneurial spirit of BIOCORP while driving further investment in the organization.
The proposed transaction, subject to customary regulatory approvals, would be followed by a mandatory simplified tender offer for the remaining outstanding shares in BIOCORP and, if applicable legal requirements are met, a mandatory squeeze-out of the remaining shareholders and delisting of BIOCORP.
Novo Nordisk’s pursuit of this strategic acquisition demonstrates its commitment to advancing innovation in the healthcare sector and its dedication to improving the lives of patients through the development of novel treatment and monitoring solutions.
Read More News: Click Here